Leucine-Rich Repeat Serine-Threonine Protein Kinase-2
"Leucine-Rich Repeat Serine-Threonine Protein Kinase-2" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A serine/threonine protein kinase with GTPase activity that contains 12 LEUCINE-rich repeats in its central region and 7 WD repeats C-terminal to its kinase and GTPase domains. It localizes to TRANSPORT VESICLES; the OUTER MITOCHONDRIAL MEMBRANE; and the GOLGI APPARATUS. It functions in PROTEIN TRANSPORT; regulates neuron morphology in the central nervous system, and also functions in the trafficking of SYNAPTIC VESICLES. Mutations in the LRRK2 gene have been identified in autosomal dominant cases of PARKINSON DISEASE (PARK8).
| Descriptor ID |
D000071158
|
| MeSH Number(s) |
D08.811.913.696.620.682.700.534 D12.776.637.750
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Leucine-Rich Repeat Serine-Threonine Protein Kinase-2".
Below are MeSH descriptors whose meaning is more specific than "Leucine-Rich Repeat Serine-Threonine Protein Kinase-2".
This graph shows the total number of publications written about "Leucine-Rich Repeat Serine-Threonine Protein Kinase-2" by people in this website by year, and whether "Leucine-Rich Repeat Serine-Threonine Protein Kinase-2" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2005 | 0 | 1 | 1 |
| 2006 | 0 | 2 | 2 |
| 2007 | 0 | 4 | 4 |
| 2009 | 0 | 2 | 2 |
| 2010 | 0 | 3 | 3 |
| 2011 | 0 | 1 | 1 |
| 2013 | 0 | 2 | 2 |
| 2015 | 0 | 1 | 1 |
| 2016 | 0 | 1 | 1 |
| 2019 | 0 | 1 | 1 |
| 2020 | 0 | 1 | 1 |
| 2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Leucine-Rich Repeat Serine-Threonine Protein Kinase-2" by people in Profiles.
-
Parkinson's disease variant detection and disclosure: PD GENEration, a North American study. Brain. 2024 Aug 01; 147(8):2668-2679.
-
Preclinical and clinical evaluation of the LRRK2 inhibitor DNL201 for Parkinson's disease. Sci Transl Med. 2022 06 08; 14(648):eabj2658.
-
Lysosome and Inflammatory Defects in GBA1-Mutant Astrocytes Are Normalized by LRRK2 Inhibition. Mov Disord. 2020 05; 35(5):760-773.
-
Lrrk2 alleles modulate inflammation during microbial infection of mice in a sex-dependent manner. Sci Transl Med. 2019 09 25; 11(511).
-
Parkinson's disease age at onset genome-wide association study: Defining heritability, genetic loci, and a-synuclein mechanisms. Mov Disord. 2019 06; 34(6):866-875.
-
Regulation of myeloid cell phagocytosis by LRRK2 via WAVE2 complex stabilization is altered in Parkinson's disease. Proc Natl Acad Sci U S A. 2018 05 29; 115(22):E5164-E5173.
-
LRRK2(I2020T) functional genetic interactors that modify eye degeneration and dopaminergic cell loss in Drosophila. Hum Mol Genet. 2017 04 01; 26(7):1247-1257.
-
The LINK-A lncRNA activates normoxic HIF1a signalling in triple-negative breast cancer. Nat Cell Biol. 2016 Feb; 18(2):213-24.
-
Discovery of LRRK2 inhibitors using sequential in silico joint pharmacophore space (JPS) and ensemble docking. Bioorg Med Chem Lett. 2015 Jul 01; 25(13):2713-9.
-
Unaltered striatal dopamine release levels in young Parkin knockout, Pink1 knockout, DJ-1 knockout and LRRK2 R1441G transgenic mice. PLoS One. 2014; 9(4):e94826.